P/B
3,1
Korsana Biosciences
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
2018
(8 years)
Founded
2019
(7 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
8,3
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
9,2
EPS
—
Market Cap
Market Cap
15,7M
EV
14,3M
EV/Revenue
7,5
EV/EBITDA
-2,1
EV/EBIT
-2,1
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-18,4%
Total Yield
-18,4%
Payout
0%
Retained Earnings
-276M
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
84,1%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
1%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
-12%
CAGR Op. Income 5Y
-37,3%
CAGR Net Income 5Y
-37%
CAGR EPS 5Y
-47%
CAGR OCF 5Y
-38,1%
Leverage
N.D./EBITDA
0,2
Debt/Equity
0%
Current Ratio
0,8
Quick Ratio
0,8
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!